PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
19567093-10	2009	(5) The mean EPO doses 6, 8 and 12 weeks after treatment of the intravenous iron sucrose group were significantly lower than that before treatment and those of the oral medication group (all P < 0.05).	Ferric Oxide, Saccharated	76-88	erythropoietin	Homo sapiens	13-16	
31894555-11	2020	CONCLUSIONS: A monthly maintenance intravenous dose of 100 mg iron sucrose may be a practical, effective, and safe in the short term, treatment of anemia in PD patients resulting in improved hemoglobin levels, iron indices, and erythropoietin response.	Ferric Oxide, Saccharated	62-74	erythropoietin	Homo sapiens	228-242	
19567093-16	2009	Infusing intravenous iron sucrose 200 mg every two weeks can maintain the serum iron parameters and hemoglobin level in maintenance peritoneal dialysis patients and n permits reduction of the required dose of EPO.	Ferric Oxide, Saccharated	21-33	erythropoietin	Homo sapiens	209-212	
16891647-0	2006	Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients.	Ferric Oxide, Saccharated	43-55	erythropoietin	Homo sapiens	92-99	
18212498-40	2008	iron sucrose 100 mg per week can maintain serum iron parameters and Hb levels in Chinese patients on maintenance hemodialysis and can permit reductions in the required dose of EPO.	Ferric Oxide, Saccharated	0-12	erythropoietin	Homo sapiens	176-179	
19506383-0	2009	Selective use of recombinant human erythropoietin in pregnant patients with severe anemia or nonresponsive to iron sucrose alone.	Ferric Oxide, Saccharated	110-122	erythropoietin	Homo sapiens	35-49	
16431410-0	2005	Low incidence of adverse events following 90-minute and 3-minute infusions of intravenous iron sucrose in children on erythropoietin.	Ferric Oxide, Saccharated	90-102	erythropoietin	Homo sapiens	118-132	
16431410-2	2005	METHODS: Two prospective observational studies were undertaken to characterize the adverse events following iron sucrose administration in children with renal impairment and on erythropoietin.	Ferric Oxide, Saccharated	108-120	erythropoietin	Homo sapiens	177-191	
17660651-0	2002	Effect of intravenous iron saccharate on the requirements of erythropoietin in hemodialysis patients.	Ferric Oxide, Saccharated	22-37	erythropoietin	Homo sapiens	61-75	
15363053-1	2004	METHODS AND RESULTS: Oxidative stress was examined in 19 erythropoietin-treated haemodialysis patients who were receiving 100 mg of iron sucrose every 2 weeks by two intravenous methods, rapid injection and slow infusion.	Ferric Oxide, Saccharated	132-144	erythropoietin	Homo sapiens	57-71	
14607997-11	2003	therapy with dextran-free iron compounds, such as iron sucrose, optimizes epoetin therapy with no direct evidence of any short-term or long-term complications.	Ferric Oxide, Saccharated	50-62	erythropoietin	Homo sapiens	74-81	
11513178-13	2001	CONCLUSIONS: Serum erythropoietin, sTfR, and transferrin concentrations have the potential to predict the response to iron sucrose therapy in IBD-associated anemia.	Ferric Oxide, Saccharated	118-130	erythropoietin	Homo sapiens	19-33	
18212409-4	1999	In this study we found that 1000 mg of element iron (given as iron saccharate) per moth was effective in maintaining hematocrit and hemoglobin at 33% and 110 gm/L respectively, and reducing the erythropoietin (EPO) dosage by about 20% in maintenance hemodialysis patients who were iron-replete.	Ferric Oxide, Saccharated	62-77	erythropoietin	Homo sapiens	194-208	
11262469-7	2001	CONCLUSION: Adjuvant recombinant human erythropoietin safely enhanced the efficacy of iron sucrose in the treatment of gestational iron-deficiency anemia resistant to orally administered iron alone.	Ferric Oxide, Saccharated	86-98	erythropoietin	Homo sapiens	39-53	
11134438-12	2001	CONCLUSIONS: In stable VLBW infants receiving EPO treatment, parenteral supplementation with 2 mg/kg/day of iron sucrose results in a small, but significant, augmentation of erythropoiesis beyond that of r-HuEPO and enteral iron alone.	Ferric Oxide, Saccharated	108-120	erythropoietin	Homo sapiens	46-49	
11157370-2	2001	In a multicenter North American clinical trial, we determined the efficacy and safety of iron sucrose therapy in patients with dialysis-associated anemia, evidence of iron deficiency, and below-target hemoglobin (Hgb) levels despite epoetin therapy.	Ferric Oxide, Saccharated	89-101	erythropoietin	Homo sapiens	233-240	
18212409-4	1999	In this study we found that 1000 mg of element iron (given as iron saccharate) per moth was effective in maintaining hematocrit and hemoglobin at 33% and 110 gm/L respectively, and reducing the erythropoietin (EPO) dosage by about 20% in maintenance hemodialysis patients who were iron-replete.	Ferric Oxide, Saccharated	62-77	erythropoietin	Homo sapiens	210-213	
7968018-0	1994	Intravenous iron-sucrose complex to reduce epoetin demand in dialysis patients.	Ferric Oxide, Saccharated	12-24	erythropoietin	Homo sapiens	43-50	
1361844-13	1992	PIC is as effective as ferrous sulfate in sustaining erythropoiesis in patients receiving epoetin alfa.	Ferric Oxide, Saccharated	0-3	erythropoietin	Homo sapiens	90-97